Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis.
CONCLUSION: RFA-sorafenib combination may not be a better approach for patients with HCC. More well-designed randomized clinical trials (RCTs) should be performed before we finally arrive at a rational comprehension about the therapeutic value of the discussed options.
PMID: 29332348 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Biology | Cancer & Oncology | Carcinoma | China Health | Clinical Trials | Databases & Libraries | Hepatocellular Carcinoma | Liver Cancer | Study